Infectious disease researchers at The University of Texas at Austin and other institutions in Hong Kong, mainland China and France have concluded there is a high probability that the deadly Wuhan coronavirus spread beyond Wuhan and other quarantined cities before Chinese officials were able to put a quarantine in place. At least 128 cities in China outside of the quarantine zone, including cities with no reported cases to date, had a greater than even risk of exposure, according to a paper currently in press with Emerging Infectious Diseases , a journal of the U.S. Centers for Disease Control and Prevention.
Based on comprehensive travel data from location-based services and modeling of the disease done at UT Austin's Texas Advanced Computing Center, 128 cities in China had a 50% chance or greater risk that someone exposed to the virus traveled there before the quarantine began. The team also estimated there were 11,213 cases of the coronavirus in Wuhan by the time of the quarantine on Jan. 22 -- a rate 10 times higher than the reported cases.
"This risk assessment identified several cities throughout China likely to be harboring yet undetected cases of [Wuhan coronavirus] and suggests that early 2020 ground and rail travel seeded cases far beyond the Wuhan region quarantine," write the authors.
As of Feb. 4, officials have confirmed 425 fatalities from the virus, all but two in mainland China, and more than 20,000 confirmed cases spread across the world.
The paper shows there is a 99% chance that at least one patient carrying the virus traveled to the cities of Beijing, Guangzhou, Shenzhen and Shanghai by the time the quarantine was put in place for the city of Wuhan on Jan. 23. The quarantine has since expanded to include cities with populations totaling 60 million people. Beijing reported its first fatality from the virus on Jan. 27. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology